BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.34 (+2.25%)

Stability Price

Overvalued by 98.60%

Company Metrics

  • 0 P/E
  • 64.68 P/S
  • 17.05 P/B
  • -0.72 EPS
  • -229.93% Cash ROIC
  • 1.26 Cash Ratio
  • 0 / N/A % Dividend
  • 893,690.00 Avg. Vol.
  • 1.12B Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Bank of America Recommendation on BioCryst Pharmaceuticals, Inc. (NASDAQ ...
Insider Trading Report - Jul 6, 2015
Bank of America upgrades its view on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) according to the research report released by the firm to its investors.
Durham's BioCryst cuts $45 million deal with Australian firm
Triangle Business Journal - Jun 17, 2015
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) licensed its recently approved flu treatment Rapivap in a deal that could bring the company $45 million plus sales royalties.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has licensed RAPIVAB ... - Inside Trade
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza ... - GlobeNewswire (press release)
Stock Report on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
Street Report - Jul 1, 2015
[Zacks] BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)(TREND ANALYSIS) was a big mover last session with its shares rising nearly 10% on the day.
Top Growth Pick: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Enterprise Leader
BioCryst Pharmaceuticals Stock Rating Upgraded by Bank of America (BCRX) - The Legacy
BofA Upgrades Biocryst Pharma; Optimistic About Next Gen Drug
Benzinga - Jun 30, 2015
In a report published Tuesday, BofA Merrill Lynch analyst Tazeen Ahmad upgraded the rating on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) from Neutral to Buy, while raising the price target from $12 to $19. Analyst Tazeen Ahmad commented that ...
Analysts at Bank of America Upped BioCryst Pharmaceuticals (NASDAQ:BCRX ... - OctaFinance.com
BioCryst Pharmaceuticals Upgraded to "Buy" by Bank of America (BCRX) - sleekmoney
Company Shares of BioCryst Pharmaceuticals, Inc. Rally 3.28%
OTC Outlook - Jul 6, 2015
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose by 3.28% in the past week and 15.8% for the last 4 weeks.
BioCryst Pharmaceuticals, Inc. Short Interest Update
Insider Trading Report - Jun 25, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), According to the latest information the short interest in BioCryst Pharmaceuticals, Inc. shot up by 0.8% or 95,847 shares. The final shorts are 16.9% of the total floated shares. The positions increased ...
Biocryst Pharmaceuticals Inc (BCRX) Discloses SEC Form 4 Insider Selling ... - Money Flow Index
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Stock Insider Sale - Jon ... - OctaFinance.com
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
Motley Fool - Apr 1, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
Ebola Finances Coming Back in the News - 24/7 Wall St.
BioCryst Awarded BCX4430 Advanced Development Contract - MarketWatch
Inside Deal: Thomas Staab Sold 3000 Shares of BioCryst Pharmaceuticals, Inc ...
OctaFinance.com - Jun 2, 2015
The insider Thomas Staab who is Senior Vice President and CFO of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 15.10 +0.54 3.71% unloaded 3,000 shares of the Alabama-based company valued at near $36,000 US Dollars which is calculated based on ...
Stock Runners: Regulus Therapeutics Inc. (NASDAQ:RGLS), BioCryst ... - Stock Transcript
Company Insider Thomas R Ii Staab Sells 3000 Shares of Biocryst ... - The Daily Rover
Stock to Follow: BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
Street Report - Jun 17, 2015
[EDGAR] BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)(TREND ANALYSIS) The Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc. (the “Company”), was held on May 20, 2015 for the purpose of: (i) electing one ...
Zacks Rating on BioCryst Pharmaceuticals, Inc. - American Trade Journal
Closing Bell Reports: BioCryst Pharmaceuticals, Inc. (BCRX), Archer-Daniels ... - WallStreet Scope
BioCryst Pharmaceuticals, Inc. Analyst Rating Update
Insider Trading Report - Jun 12, 2015
Biocryst Pharmaceuticals (NASDAQ:BCRX) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1.57 by 7 Wall Street Analysts. 5 analysts have added the counter in their list ...